HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. - Wikidata - awgldk - TriplyDB

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

http://www.wikidata.org/entity/Q41308137

about

Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors Drugging topoisomerases: lessons and challenges Synthetic lethal screens as a means to understand and treat MYC-driven cancers HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo.Dissect the Dynamic Molecular Circuits of Cell Cycle Control through Network Evolution Model.TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples.Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.Immunohistochemistry for myc predicts survival in colorectal cancer.HER2 in solid tumors: more than 10 years under the microscope; where are we now?c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer.A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.Copy number increase of HER-2 in colorectal cancers.Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics.HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF Cause and consequences of genetic and epigenetic alterations in human cancer.Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis.Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer.Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.KRAS and TP53 mutations in colorectal carcinoma.Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.Genome-wide analyses of long noncoding RNA expression profiles in lung adenocarcinoma.TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.Expression of Wnt-signaling pathway genes and their associations with miRNAs in colorectal cancer.Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.

P2860

Q24595585-EC7E3A18-E0BA-4781-BCDE-78DEE26A8040 Q27000099-6606735A-1141-4973-8D0D-4F7005C0E10A Q27006010-E1960322-02ED-42A7-9C77-A46076BFC27B Q27852057-E6F5AC4A-C9C4-49B9-A4BA-A3BE37B2A98E Q33404601-75C4A76E-DF6E-472F-9603-DF6EEB71940E Q33561346-BD22D1A2-B5FB-4DF7-A8C2-27DE0D1736B2 Q34044864-6B6CDCFB-1520-4B5E-81BC-77BA786745E3 Q34164365-9A59BE0E-439C-4053-88EC-435EBB4C1C03 Q34442193-108E4D67-4FA0-4EF6-BAA8-153074DD4EE0 Q35011886-2966B2BD-D070-40B7-BBC5-01196D44952F Q35087649-10B8A9DE-8F67-4CE5-AAAD-096E6DFA0BB3 Q35211263-C97D654C-5ADD-4EE0-B521-1082385C0017 Q35795297-AC9F1154-90ED-43A6-A425-3104F84E69BA Q35921206-C16CF66C-1597-4C36-A6DD-A252CEFE3E97 Q36135873-616E8E59-FD96-441B-A8E0-68C40029C03B Q36388523-5BA2FA49-D13E-4848-9CDD-2CED743A726B Q36636356-D9741A8D-5928-4F14-8A59-36CCBC0B8081 Q36655951-13D7E991-5BBF-42B7-AD34-85D916F617E2 Q36728796-1B973999-CB7B-4693-B557-BB70253AC940 Q37149773-B6FF584B-E31A-4AD2-8CF3-1B64DBFC9AE1 Q37511752-A162C81D-C8F9-4D91-BB3A-A5A44A1A9D31 Q38096413-CF6F379B-0887-4315-A5A4-426F40BE6E11 Q38621219-2C4AB7CA-5048-4F2C-85C0-F0BFB334CCFA Q38648453-4ED2F7E1-DE10-4CE5-8E4A-FAE032094D6E Q38827897-A1FB2F40-3D44-4878-AE7B-64DC537838C8 Q39011091-7C5CB85C-6067-4C2C-B7D6-E8D5090DD886 Q39186813-8B129E81-1333-4FD9-822E-F8AD5FEC1FDC Q39612011-5FC5C716-1D75-4812-872C-2C019012CCE6 Q39680556-32F2861E-D40C-4F25-8FDB-96A20EDA98D3 Q42362550-E5BBB50E-1ED5-49B5-BF00-AC4ED2671005 Q43635123-59683402-B4E7-4A38-AF52-D4120F202CA9 Q47164589-721BA88D-F4F8-444F-A6B2-9592FAD66A31 Q48845796-E60E75D9-440D-4D35-9710-F43D231698CF Q49787639-2C17AF9E-28E2-4C16-BEF9-ED0843DA9A41 Q50096089-6286EF55-BCBE-4E47-848D-C339A25062A5 Q51776452-5B22343C-AC6E-44B1-9710-3151A2FB9CED Q53080639-98181BC8-C2A1-4B6F-AFB1-EE9E967A9F7C Q54469155-8263CF67-F5C9-43BE-9896-B0ABC11AA7AA Q54540314-5A10439D-B144-46FD-8D56-63E6589DEA31

P2860

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

http://www.wikidata.org/entity/Q41308137

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

@en

type

label

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

@en

prefLabel

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

@en

P1433

Q41308137-69B4F979-04DF-41B8-A5AB-82EA5A7D84F2

P1476

Q41308137-915CC0DF-1247-4212-AA32-D6B64CCB3114

P2093

Q41308137-16991796-EF40-4236-B7FB-F8CD1DF2B8DE

Q41308137-1983CC81-20CC-4DF4-9DA0-A9CD01754C06

Q41308137-2FA43C3C-3DC6-4302-B910-6B7E03420224

Q41308137-384BC5B7-840F-4EE4-89B0-BC3A6241F4DA

Q41308137-43EA64C1-7F37-49F0-A0C4-D7150D201239

Q41308137-488AD7C2-CCDF-4F2A-B136-997E63617805

Q41308137-50239BB5-4BEB-492F-8D02-3E9CBC7D1CC7

Q41308137-69D3308C-E00B-4D2B-9840-325EB5EC4F0E

Q41308137-86EF2D3E-AD78-48A1-B5CE-44BFFD431122

Q41308137-9BC944A0-44F3-4E18-A7E4-C25F288A8BCF

P2860

Q41308137-100F7C7C-F0EF-4406-B27E-C8C342F588E2

Q41308137-1FA440B3-C13C-4AE7-82ED-38B47AD4BE8F

Q41308137-29427062-3EA4-4693-AD82-EC0CBDFD648C

Q41308137-4243C394-6169-4E79-933D-5BE658BB85DE

Q41308137-5369F8D0-1092-44F4-BEA7-0DD0A18D82B0

Q41308137-665D5AE5-4A9D-42C0-B488-D3D4C3B17D7C

Q41308137-76BFADD6-EC7A-48CA-B76D-74D00A88259A

Q41308137-7F5412E5-EE59-4780-B772-2633E0F1F2A1

Q41308137-85D85B9B-6FC6-4E28-90CE-7FD055766023

Q41308137-A36F54CF-B459-4348-978B-F58D7508341D

P304

Q41308137-2AE4F7AA-A439-4341-A824-732EB3D2DE29

P31

Q41308137-A196F58E-323F-448E-B98A-EDE9EDC736A9

P356

Q41308137-CD57DA59-F085-4711-9491-E6B47A01CC42

P407

Q41308137-29CC0EE4-F4C0-4ED5-A190-835C35FE8922

P433

Q41308137-3508F6AD-9145-4A40-8CF7-58EC9ED9E92A

P478

Q41308137-5587244B-01D3-44DA-BD49-737E58775950

P50

Q41308137-38A67475-7EE9-41F8-B65E-D172ABB3781C

Q41308137-6D5D2EDD-EA48-41DD-A64A-B4A6D759B544

P577

Q41308137-DC2C9543-7234-403F-B66C-47F385DB7C05

P5875

Q41308137-3F9F0A67-6568-4086-ADFC-73BC832EF212

P698

Q41308137-EE4E64DC-C430-449C-AD02-BD3523DA0DC9

P921

Q41308137-74F66EB3-70F9-40CC-9BD2-76C398C4474F

P932

Q41308137-CF5E1D2E-0236-40C6-BE44-9D576721CCDD

P356

JCP.2006.038281

P1433

Journal of Clinical Pathology

P1476

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

@en

P2093

Abdul K Siraj

http://www.w3.org/2001/XMLSchema#string

Adnan Ezzat

http://www.w3.org/2001/XMLSchema#string

Coya Tapia

http://www.w3.org/2001/XMLSchema#string

Fouad Al-Dayel

http://www.w3.org/2001/XMLSchema#string

Guido Sauter

http://www.w3.org/2001/XMLSchema#string

Hadeel Al-Mana

http://www.w3.org/2001/XMLSchema#string

Hedvika Novotny

http://www.w3.org/2001/XMLSchema#string

Khawla Al-Kuraya

http://www.w3.org/2001/XMLSchema#string

Luigi Terracciano

http://www.w3.org/2001/XMLSchema#string

Martina Mirlacher

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Intake of fat, meat, and fiber in relation to risk of colon cancer in men.

Novel pattern of P53 mutation in breast cancers from Austrian women.

Smart drugs: tyrosine kinase inhibitors in cancer therapy.

A prospective study of dietary fat and risk of prostate cancer.

Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence.

Tissue microarrays in drug discovery.

Chromosomal imbalances in the colorectal carcinomas with microsatellite instability

P304

768-772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2006.038281

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6903472

http://www.w3.org/2001/XMLSchema#string

P698

16882699

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

1995777

http://www.w3.org/2001/XMLSchema#string